Portia Smith’s most vivid memories of her daughter’s first year are of tears. Not the baby’s. Her own.
“I would just hold her and cry all day,” Smith said.
At 18, Smith was caring for two children, 4-year-old Kelaiah and newborn Nelly, with little help from the partner in her abusive relationship. The circumstances were difficult, but she knew the tears were more than that.
“I really didn’t have a connection for her,” said Smith, now a motivational speaker and mother of three living in Philadelphia. “I didn’t even want to breastfeed because I didn’t want that closeness with her.”
GISENYI, Rwanda (Reuters) – An Ebola survivor has fallen ill with the disease for a second time in eastern Congo, the Congolese health authorities said on Sunday, saying it was not yet clear if it was a case of relapse or reinfection.
The Ebola outbreak in Democratic Republic of Congo has infected over 3,300 people and killed more than 2,200 since the middle of last year, making it the second worst year on record.
KUALA LUMPUR (Reuters) – A three-month-old Malaysian infant has been diagnosed with polio, the first case reported in the country in nearly three decades, a top health official said on Sunday.
The baby boy from Tuaran in Malaysia’s Sabah state on Borneo island tested positive for polio on Friday after being admitted to hospital with a fever and muscle weakness, Director General of Health Noor Hisham Abdullah said in a statement.
“The patient is being treated in an isolation ward and is in stable condition, but still requires assistance to breathe,” he said.
SAN DIEGO — When Mary Prehoden gets dressed for work every morning, her eyes lock on the bite-shaped scar on her chest.
It’s a harsh reminder of one of the worst days of her life. Prehoden, a nurse supervisor at Scripps Mercy Hospital San Diego, was brutally attacked last year by a schizophrenic patient who was off his medication. He lunged at her, threw her to the ground, repeatedly punched and kicked her, and bit her so hard that his teeth broke the skin and left her bleeding.
FILE PHOTO: A nurse walks along the hallways of a health center in Lepanto, Arkansas, U.S., May 2, 2018. REUTERS/Karen Pulfer Focht
(This Dec. 5 story corrects first paragraph to say growth was slower not declined in previous years, removes reference to projected spending in eighth paragraph)
(Reuters) – U.S. healthcare spending grew faster in 2018 after two slower growth years, a government health agency reported on Thursday.
The total national health expenditures last year grew 4.6% to $3.6 trillion, or $11,172 per person, boosted by faster growth in private health insurance and government-sponsored health insurance programs, the U.S. Centers for Medicare and Medicaid Services (CMS) said.
THURSDAY, Dec. 5, 2019 (HealthDay News) — Imagine a blood test that could spot whether you are aging too quickly.
New research suggests it’s not the stuff of science fiction anymore.
The scientists analyzed plasma — the cell-free, fluid part of blood — from more than 4,200 people between the ages of 18 and 95, and found a link between 373 proteins and aging.
“We’ve known for a long time that measuring certain proteins in the blood can give you information about a person’s health status — lipoproteins for cardiovascular health, for example,” said study senior author Tony Wyss-Coray. He’s co-director of the Alzheimer’s Disease Research Center at Stanford University in California.
(Reuters) – The U.S. Food and Drug Administration on Friday approved Amgen Inc’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade, according to the regulator’s website.
FILE PHOTO: An Amgen sign is seen at the company’s office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith
The biosimilar, Avsola, has the same chemical components, dosage form and strength as Remicade and would treat a range of autoimmune disorders.
Amgen did not give the pricing of the drug immediately, but said is confident to compete in the biosimilar market.
(Reuters) – Alexion Pharmaceuticals Inc said on Friday its board of directors had unanimously rejected hedge fund Elliott Management’s push for a “proactive sale” process of the entire company because it would not be in the best interest of shareholders.
Alexion has been fighting to maintain its leadership in treating certain rare blood disorders, and has embarked on a string of acquisitions to boost its pipeline of rare disease drugs. In October, it agreed to buy rival Achillion Pharmaceuticals Inc for about $930 million.